Aiping Shi

Aiping Shi


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2015 in Oncology Reports
Verified
Journal Article
Closed access
GZGang Zhao
Gang Zhao
ASAiping Shi
Aiping Shi
ZFZhimin Fan
Zhimin Fan
YDYe DU
Ye DU
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications

1 January 2017
Verified
Journal Article
Closed access
ZLZhenyu Liu
Zhenyu Liu
ASAiping Shi
Aiping Shi
DSDong Song
Dong Song
BHBing Han
Bing Han
ZZZhiru Zhang
Zhiru Zhang
ZFZhimin Fan
Zhimin Fan

18 October 2018 in Oncology Reports
Verified
Journal Article
Closed access
PDF file
WLWenlong Li
Wenlong Li
HYHongmei Yang
Hongmei Yang
XLXiaoli Li
Xiaoli Li
LHLou Han
Lou Han
NXNing Xu
Ning Xu
ASAiping Shi
Aiping Shi
The present study aimed to investigate the efficacy of five signaling pathway inhibitors, N-[N-(3,5‑difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester, vismodegib, salinomycin, ruxolitinib and stattic, as novel therapeutic agents that target breast cancer stem cells (BCSCs) in triple-negative breast cancer (TNBC). The in vitro anti-proliferative, anti-invasive, pro-apoptotic and inhibitory effects on BCSC self-renewal of these signaling pathway inhibitors on the TNBC stem cell line HCC38 were examined by MTT assays, Matrigel invasion assays, flow cytometry and suspension mammosphere assays, respectively. For the in vivo study, another TNBC stem cell line, HCC1806, pretreated with these signaling pathway inhibitors, was inoculated into female nonobese diabetic/severe combined immunodeficient mice, and the tumor volumes were measured following tumor formation. Treatment of HCC38 cells with each signaling pathway inhibitor significantly decreased TNBC cell proliferation, cell invasion and mammosphere formation while inducing cell apoptosis by inhibiting the protein expression or phosphorylation of downstream signaling molecules. In the xenograft mouse models, tumor formation and growth of HCC1806 cells pretreated with each signaling pathway inhibitor were effectively suppressed. Treatment with these signaling pathway inhibitors may provide a novel therapeutic strategy against TNBC by targeting BCSCs, thus providing promising insight for clinical applications in patients with TNBC.

1 May 2018 in Patient Preference and Adherence
Verified
Journal Article
Open access
PDF file
PGPin Gao
Pin Gao
LYLili You
Lili You
DWDi Wu
Di Wu
ASAiping Shi
Aiping Shi
QMQing Miao
Qing Miao
ZFZhimin Fan
Zhimin Fan
Background: Postoperative endocrine therapy is known to reduce recurrence and mortality in patients with estrogen receptor (ER)- or progestogen receptor (PR)-positive breast cancer. Correlates and determinants of compliance with endocrine therapy among Chinese patients with breast cancer are not known. The aim of this study was to elucidate the efficacy and adherence of endocrine therapy in China and suggest effective improvements on the adherence. Patients and methods: We analyzed the survival of 1,110 patients eligible for endocrine therapy and adherence of 699 patients to endocrine therapy. Kaplan–Meier curves, log-rank tests and Cox proportional hazard models were used to evaluate survival, and logistic regression models were used to assess variables associated with treatment adherence. Results: Long-term endocrine therapy was associated with lower recurrence rate (HR 0.72; 95% CI 0.56–0.93; p=0.013). Adherence to endocrine therapy was only 63.1%. Sociodemographic characteristics of patients, clinical- and medication-related characteristics and patients’ attitudes were associated with adherence to endocrine therapy. Conclusion: Adherence to endocrine therapy in Chinese patients with ER+/PR+ breast cancer was <65%. Both patients and physicians should take progressive steps to improve the rate of adherence.

15 August 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ZZZhu Zhu
Zhu Zhu
LLLing Li
Ling Li
ZYZhong Ye
Zhong Ye
TFTong Fu
Tong Fu
YDYe Du
Ye Du
ZFZhimin Fan
Zhimin Fan
The prognostic value of routine laboratory variables in breast cancer has been largely overlooked. Based on laboratory tests commonly performed in clinical practice, we aimed to develop a new model to predict disease free survival (DFS) after surgical removal of primary breast cancer. In a cohort of 1,596 breast cancer patients, we analyzed the associations of 33 laboratory variables with patient DFS. Based on 3 significant laboratory variables (hemoglobin, alkaline phosphatase, and international normalized ratio), together with important demographic and clinical variables, we developed a prognostic model, achieving the area under the curve of 0.79. We categorized patients into 3 risk groups according to the prognostic index developed from the final model. Compared with the patients in the low-risk group, those in the medium- and high-risk group had a significantly increased risk of recurrence with a hazard ratio (HR) of 1.75 (95% confidence interval [CI] 1.30–2.38) and 4.66 (95% CI 3.54–6.14), respectively. The results from the training set were validated in the testing set. Overall, our prognostic model incorporating readily available routine laboratory tests is powerful in identifying breast cancer patients who are at high risk of recurrence. Further study is warranted to validate its clinical application.

1 September 2013 in Pathology - Research and Practice
Verified
Journal Article
Closed access
YDYi Dong
Yi Dong
LBLi-Rong Bi
Li-Rong Bi
NXNing Xu
Ning Xu
HYHong-Mei Yang
Hong-Mei Yang
HZHai-Tao Zhang
Hai-Tao Zhang
ZFZhi-Min Fan
Zhi-Min Fan